Karriereverlauf von Martin Bott
Ehemalige bekannte Positionen von Martin Bott
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| INMED PHARMACEUTICALS INC. | Director/Board Member | 13.01.2017 | 31.08.2019 |
| Independent Dir/Board Member | 13.01.2017 | 31.08.2019 | |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01.01.1988 | 01.12.2017 |
| COLUCID PHARMACEUTICALS INC | Director/Board Member | 01.03.2017 | - |
Ausbildung von Martin Bott
| Universität zu Köln | Undergraduate Degree |
| University of South Carolina | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
| Kanada | 2 |
| Deutschland | 2 |
Operativ
| Director/Board Member | 2 |
| Independent Dir/Board Member | 1 |
| Graduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| INMED PHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
CoLucid Pharmaceuticals, Inc.
 CoLucid Pharmaceuticals, Inc. BiotechnologyHealth Technology CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Martin Bott
- Erfahrung
